drugset / Trial / NCT01520389
Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study is a Phase 1 and pharmacologic open-labeled dose-escalation trial using a "3+3" design, evaluating MM-151 at varying dose levels and frequencies, and subsequently in combination with irinotecan.
Timeline
- Start
- 2012-01
- Primary completion
- 2015-12
- Completion
- 2016-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MM-151 | Unknown | — | — |
| Background | Irinotecan | Small molecule | 180 mg/m2 | — |